1. The 'News In Brief' post for w/c 8th October is now available Guest, click here.
    Dismiss Notice

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome - Evidence for an autoimmune disease

Discussion in 'BioMedical ME/CFS Research' started by Daisymay, Apr 13, 2018.

Tags:
  1. Daisymay

    Daisymay Senior Member (Voting Rights)

    Messages:
    309
    Likes Received:
    3,487
    https://www.ncbi.nlm.nih.gov/pubmed/29635081

    Autoimmun Rev. 2018 Apr 7. pii: S1568-9972(18)30088-0. doi: 10.1016/j.autrev.2018.01.009. [Epub ahead of print]

    Myalgic Encephalomyelitis/Chronic Fatigue Syndrome - Evidence for an autoimmune disease.
    Sotzny F1, Blanco J2, Capelli E3, Castro-Marrero J4, Steiner S1, Murovska M5, Scheibenbogen C6; European Network on ME/CFS (EUROMENE).
    Author information

    Abstract
    Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a frequent and severe chronic disease drastically impairing life quality. The underlying pathomechanism is incompletely understood yet but there is convincing evidence that in at least a subset of patients ME/CFS has an autoimmune etiology. In this review, we will discuss current autoimmune aspects for ME/CFS. Immune dysregulation in ME/CFS has been frequently described including changes in cytokine profiles and immunoglobulin levels, T- and B-cell phenotype and a decrease of natural killer cell cytotoxicity. Moreover, autoantibodies against various antigens including neurotransmitter receptors have been recently identified in ME/CFS individuals by several groups. Consistently, clinical trials from Norway have shown that B-cell depletion with rituximab results in clinical benefits in about half of ME/CFS patients. Furthermore, recent studies have provided evidence for severe metabolic disturbances presumably mediated by serum autoantibodies in ME/CFS. Therefore, further efforts are required to delineate the role of autoantibodies in the onset and pathomechanisms of ME/CFS in order to better understand and properly treat this disease.

    KEYWORDS:
    Autoantibodies; Autoimmune; Biomarker; Chronic Fatigue Syndrome; Myalgic Encephalomyelitis

    PMID:

    29635081

    DOI:

    10.1016/j.autrev.2018.01.009
     
  2. strategist

    strategist Senior Member (Voting Rights)

    Messages:
    830
    Likes Received:
    8,407
    I'm getting the impression that several groups wanted to publish a B cell autoimmunity paper in case of a positive Rituximab trial.
     
    adambeyoncelowe and Inara like this.
  3. Trish

    Trish Moderator Staff Member

    Messages:
    6,903
    Likes Received:
    41,115
    Location:
    UK
    Oh dear, they are out of date already.
     
  4. Andy

    Andy Committee Member

    Messages:
    3,730
    Likes Received:
    28,069
    Location:
    Hampshire, UK
    Shouldn't be really. Also, six days seems an incredibly short time for it to be accepted, does this mean it hasn't been peer reviewed? Is it exempt from that?
     
  5. Trish

    Trish Moderator Staff Member

    Messages:
    6,903
    Likes Received:
    41,115
    Location:
    UK
    If its an article gathering together evidence from other people's studies, does it need peer review?
     
  6. BruceInOz

    BruceInOz Senior Member (Voting Rights)

    Messages:
    194
    Likes Received:
    1,318
    Location:
    Tasmania
    Yes. Although that answer is only based on what would have been the norm in respected physics journals 20 years ago, so in reality I've no idea. Seven days is a very short time, but I would imagine not impossible. Maybe those asked to review it didn't have anything better to do that week and got to it straight away. I would have required more time for procrastinating though:).
     
  7. Lidia

    Lidia Established Member (Voting Rights)

    Messages:
    67
    Likes Received:
    461
    Duplicate thread merged

    Myalgic Encephalomyelitis/Chronic Fatigue Syndrome – Evidence for an autoimmune disease

    FranziskaSotznyaon behalf of the European Network on ME/CFS (EUROMENE)
    Autoimmunity Reviews
    Volume 17, Issue 6, June 2018, Pages 601-609

    I couldn’t find this anywhere here. If it already exists, mods please feel free to delete.

    I found the conclusion interesting, in that it talks of Rituximab despite the null result (submitted Jan 2018):

     
    Last edited by a moderator: Jun 11, 2018
  8. hixxy

    hixxy Established Member (Voting Rights)

    Messages:
    80
    Likes Received:
    510
    The most recent clinical trial with rituximab wasn't encouraging. Am I missing something?
     
    Invisible Woman and andypants like this.
  9. andypants

    andypants Senior Member (Voting Rights)

    Messages:
    530
    Likes Received:
    4,297
    Location:
    Norway
    No, but it’s not published yet, so if you only look at published studies rtx still looks promising. Or they chose to ignore the phase III trial to promote their own view of ME as an autoimmune disease/autoimmune component.
     
    Invisible Woman and Skycloud like this.
  10. Jonathan Edwards

    Jonathan Edwards Senior Member (Voting Rights)

    Messages:
    2,418
    Likes Received:
    26,260
    The review was accepted on January 7th. So it may now be out of date.
     
  11. Tom Kindlon

    Tom Kindlon Senior Member (Voting Rights)

    Messages:
    531
    Likes Received:
    5,060
     
    Inara and Amw66 like this.

Share This Page